Drug Profile
Research programme: diagnostic tracer agents - MediBeacon
Alternative Names: MB-202; MB-212; MB-301; MB-402Latest Information Update: 28 Feb 2021
Price :
$50
*
At a glance
- Originator MediBeacon
- Class Diagnostic agents; Imaging agents
- Mechanism of Action Diagnostic imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gastrointestinal disorders; Kidney disorders; Unspecified
Most Recent Events
- 28 Feb 2021 No recent reports of development identified for research development in Unspecified(Diagnosis) in USA (Parenteral)
- 28 Nov 2020 No recent reports of development identified for preclinical development in Kidney-disorders(Diagnosis) in USA (Parenteral)
- 28 Nov 2020 No recent reports of development identified for research development in Gastrointestinal-disorders(Diagnosis) in USA (Parenteral)